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INTRODUCTION
Adjuvant radiation therapy (RT) following breast 
conserving surgery has been shown to reduce the rates 
of local recurrence and death in breast carcinoma. De-
spite recent efforts to decrease irradiation volumes, pul-
monary toxicity remains one of the main restrictions in 
breast RT because of the exposition to high doses of ra-
diation to the chest [1] and typically presents with two 
distinct, subsequent clinical phases: acute pneumonitis 
and late fibrosis.
A number of published studies have shown data re-
garding late radiological changes and alterations in 
pulmonary function tests after breast RT and the re-
ported incidence of radiation-induced lung injury var-
ies between 4.5% and 63% in prospective studies and 
between 0.9% and 30% in retrospective studies [2]. The 
heterogeneity of the data in world literature can be at-
tributed to the different treatment techniques, different 
sites treated (regional or loco-regional RT), different de-
tections tests (functional tests, chest X-rays, computed 
tomography or high-resolution computed tomography). 
Although late lung damage is clinically asymptomatic 
in the majority of patients and often under-diagnosed 
due to the absence of screening protocols, this clinical 
entity has a potential detrimental effect of reducing the 
normal functional reserve considering the long life ex-
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Abstract
Background and purpose. Radiation therapy (RT) for breast cancer after conservative 
surgery can be life-saving but remains associated with significant late side effects, includ-
ing lung fibrosis, detected by chest CT. Aim of this study was to assess whether lung 
ultrasound (LUS) may detect late lung fibrosis through the biomarker of B-lines. 
Materials and methods. We evaluated 30 women (median age 67 years, range 46-80 
years) about 3-8 years after RT (follow up 38-101 months, median 58 months) for left (n 
= 12) or right (n = 18) breast cancer (stage 1, n = 24; stage 2, n = 6), treated with total 
dose 40.5 – 50.00 Gy with/without boost dose). In all, both treated and contralateral 
hemithorax were evaluated. LUS was performed and B-lines evaluated with a 28-region 
antero-lateral scan, from second to fifth intercostal spaces, along the mid-axillary, ante-
rior axillary, mid-clavicular, and parasternal lines. In each space, the B-lines were counted 
from 0 = black lung to 10 = white lung. The sum of B-lines in all spaces generated the 
B-line score of each hemithorax. 
Results. Median B-line score was higher in the irradiated site than in the contralateral 
control hemithorax (9, 1st-3rd quartiles: 2-23 vs 3, 1st-3rd quartiles: 1-4; P < 0.05). In the 
treated hemithorax, higher mean lung doses ( > median value of 2.7 Gy) were associated 
with more B-lines when compared to lower doses (< 2.7 Gy): 9 vs 5, p <0.001.
Conclusion. RT in female breast cancer survivors is associated with increase in B-lines 
in the targeted hemithorax, likely due to lung fibrosis, and related to the lung mean dose. 
LUS can provide a simple “echo-marker” of lung fibrosis.
Address for correspondence: Maurizio Portaluri, UO di Radioterapia, Ospedale “A. Perrino”, Strada Statale n. 7, 72100 Brindisi, Italy. E-mail: 
m.portaluri@asl.brindisi.it.
Lung uLtrasound B-Lines Late after Breast cancer radiotherapy
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
295
pectancy of patients with early-stage breast cancer [3].
Lung ultrasound (LUS) has been proven to be accu-
rate in diagnosing extravascular lung water, pulmonary 
fibrosis and pulmonary interstitial syndrome because 
these lung disorders produce a peculiar “echo-marker” 
called B-lines [5-8]. Use of ultrasonography in emer-
gency department, critical care and cardiac care units is 
becoming popular because this imaging modality is eas-
ily available, real time and free of radiation hazards in 
comparison to conventional radiological modalities [9]. 
Accordingly, LUS could offer promising tools for an ac-
curate diagnose of pulmonary complications induced 
by RT and identification of patients at risk. 
In a previous study a combined strategy of lung ul-
trasound and biochemical analysis was evaluated to di-
agnose RT-induced complications few months after RT 
completion. LUS showed effective in detecting early 
lung damage in breast conserving radiotherapy with 
minimal dose to the lung [10]. 
The current study hypothesis is that RT-induced lung 
fibrosis can be detected through B-lines at LUS, since 
this finding has previously been shown to be very sensi-
tive and specific for detection geographic localization 
and quantification of lung fibrosis, with accuracy com-
parable to the gold standard of chest CT. 
In this new study, we explore lungs of women who 
underwent breast RT post conservative surgery years 
(about 3-8) after RT completion in order to verify late 
subclinical effect and its possible relationship with dose 
and other individual parameters.
MATERIALS AND METHODS
Patient characteristics
A total of 30 women with breast cancer (median age 
67 years, range 46-80 years) who underwent adjuvant 
radiotherapy (stage I-II) were enrolled after 38-101 
months (median 58 months) after the end of RT. Eigh-
teen of these patients were treated for right and twelve 
for left breast cancer.
Clinical, demographic, and dosimetric characteristics 
are described in Table 1.
A detailed history was collected; all patients under-
went a clinical visit with a complete LUS analysis. The 
exclusion criteria were history of chronic respiratory 
disease, need for radiotherapy to regional nodes, previ-
ous concomitant malignancies. 
Ten patients had arterial hypertension treated with 
drug therapy. 
Only a patient underwent chemotherapy, while 25 
patients (83.3%) were susceptible to treatment with 
hormonal therapy. 
At the time of the LUS, no patient showed respira-
tory symptoms. Two patients  showed mild interstitial 
thickening.
A written informed consent was obtained from all 
study participants.
Radiotherapy 
The planning target volume (PTV) total dose (TD) 
prescription respectively for 16 patients and for 2 pa-
tients was of 40.05 Gy and 42.7 Gy with fraction dose 
(FD): 2.67 Gy/day for 5 days/week; for 3 patients TD 
of 45 Gy (FD: 2.5 Gy x 5 days/week) and for 9 patients 
DT of 50 Gy (FD: 2.0 Gy x 5 days/week). In 18 patients 
the PTV irradiation was followed by a boost phase to 
the tumour bed with a median dose of 10 Gy (range: 
10-13.35 Gy) and a median daily dose of 2.5 Gy (range: 
2-2.67 Gy ) for 4-6 fractions. 
The clinical target volume (CTV) and the PTV were 
defined according the International Commission on 
Radiation Units and Measurements (ICRU 50) [11]. 
Further details about radiotherapy characteristics 
have been previously published [10].
To evaluate the dose received by organs at risk, in-
Table 1
Clinical and dosimetric features of study patients
Patients 
characteristics
N = 30 Min-max (median)
Age (years) 46-80 (67.6)
RT side
 -Left 12 (40%)
 -Right 18 (60%)
Grading
 G1 9 (30%)
 G2 14 (46.7%)
 G3 7 (23.3%)
Stage
I 24 (80%)
II 6 (20%)
BMI 19.5-43 (26.7)
Systemic Therapies
CHT 1 (3.8%)
HT 25 (96.2%)
Hypertensive 
Cardiopathy
10 (33.3%)
Smokers 5 (16.6%)
Dosimetric variables
Total dose to the 
breast(Gy)
40.05-50 (40.05)
Boost 18 (60%)
Boost dose(Gy) 10-13.35 (10.7)
V95%(%) 0.0-2.4 (0.2)
V90%(%) 0.0-4.4 (0.8)
V50%(%) 1.6-9.7 (4.6)
V20Gy(%) 1.8-10.5 (4.6)
V5Gy(%) 42.9-16.2 (7.2)
LMD (Gy) 1.2-5.3 (2.67)
PTV (cc) 200-1779 (553)
LV (cc) 1457-3768 (2276)
RT = radiotherapy; BMI = body mass index; CHT = chemotherapy; HT = 
hormone therapy; V95%(%), V90%(%), V50%(%) = lung volume percentage 
that absorbed at least respectively 95%, 90% and 50% of the dose delivered to 
the target; V20Gy(%) and V5Gy(%) = lung volume percentage that absorbed 
at least 20 Gy and 5 Gy respectively; LMD (Gy) = lung mean dose; PTV (cc) = 
planning target volume; LV (cc) = lung volume; data are numbers of patients 
unless otherwise indicated.
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tegral dose-volume histogram were used, and some 
dosimetric parameters were calculated according to 
the International Commission on Radiation Units and 
Measurements (ICRU 83) [12]. 
Dose-volume parameters considered for the lung 
were as follows: (I) Dmean(Gy) that is mean dose; (II) 
VYYGy (%), which indicates the percentage of organ vol-
ume that receives at least a YY dose expressed in Gray 
(in particular were considered 5 and 20 Gy); (III) VYY% 
(%), which indicates the percentage of organ volume 
that receives at least a YY percentage of dose (in par-
ticular were considered 50, 90 and 95%).
Lung ultrasound 
The normal lung reflects ultrasound almost complete-
ly and in normal conditions reverberation phenomena 
is characterized by regular horizontal lines, at regular 
intervals and these are known as lines A. Instead, the 
alteration of the normal lung structure (eg, interstitial 
edema, fibrous thickening of the interlobular peripheral 
septa) induces the creation of perpendicular artifacts 
called B lines (Figure 1). B lines, also called “ultrasound 
lung comets” are defined as laser-like vertical hyper-
echoic reverberation artifacts (previously described as 
“comet tails”) that arise from the pleural line extend to 
the bottom of the screen without fading, and move syn-
chronously with lung sliding [5, 13, 14]. 
The echographic examination was conduct using a 
commercially available echographic equipment top of 
the range Toshiba Aplio 500 (Toshiba America Medi-
cal Systems, Inc. 2441 Michelle Dr, Tustin, CA 92780, 
United States) with a 1.9-6.0 MHz convex probe, used 
to 3.5-5.0 MHz.
Further details about the echographic examination’s 
methods have been published in a previous study [10]. 
An experienced sonographer performed all examina-
tions. 
In this work, LUS was performed and B-lines were 
evaluated with a 28-region antero-lateral scan, from 
second to fifth intercostal spaces, along the midaxillary, 
anterior axillary, mid-clavicular, and parasternal lines. 
B-lines score per patients was scored as follows: score 
0 “absent” (< 5), score 1 “mild” (5-14), score 2 “mod-
erate” (15-29), score 3 “severe” (> 30) [5]. A number 
of B-lines larger than 5 is considered abnormal. The 
sum of B-lines in all spaces generated the B-line score 
of each hemithorax. Both diseased and contralateral 
hemithorax were evaluated, in order to compare the 
chest area exposed to irradiation compared with the 
contralateral side.
Statistical analysis 
Data are expressed as mean ± standard deviation 
(normally distributed data), median and inter-quartile 
(25th, 75th) range (non-normally distributed data, such 
as B-lines) or per cent frequency (categorical data). 
Normality of the data distribution was assessed 
both visually and through Shapiro-Wilk test. With no 
evidence against the null hypothesis, i.e. normally dis-
tributed data, the following tests were planned to be 
applied: one sample Student’s t-test, in order to test the 
null hypothesis of means of B-lines equal to 0; paired 
samples t-test for the comparison of the mean numbers 
of B-lines showed by the lungs in both irradiated and 
not-irradiated sides; F-test of Snedekor-Fisher to test 
the equality of two variances. Paired samples t-test was 
adopted since we could, indeed, not assume the inde-
pendences of the samples.
With strong evidence against null hypothesis of nor-
mality of the data distribution we adopted non-para-
metric tests: Mann-Whitney test, if the hypothesis of 
equal variances was satisfied or, otherwise Wilcoxon 
test. Correlation between two variables was evaluated 
through Pearson correlation coefficient. 
Figure 1
Images of an unirradiated (panel A) and contro-lateral irradiated lung (panel B). Panel A: normal lung appareance with A-line. 
Panel B: B-line or ultrasound lung comet (ULC): laserlike vertical hyperechoic reverberation artifacts that arise from pleural line 
extended to the bottom of the screen without fading.
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Null hypothesis was rejected with p value less than 
0.05. Statistical analyses were performed using R [32]. 
RESULTS
We counted the number of B-lines in treated anterior 
hemithorax and compared it with the number in un-
treated anterior hemithorax.
B-lines were more numerous in treated (median 8.5, 
range: 0-53) vs untreated (median 3; range: 0-13) hemi-
thorax (Wilcoxon Signed rank test: p = 0.0192).
B-lines distribution in the treated and untreated 
hemithorax is shown in Figure 2. 
In the same way as described in our previous article, 
we analysed B-line score per patients and we found ab-
normal score (B-lines > 5) was present in 17/30 (51%) 
in treated vs 7/30 (21%) in untreated hemithorax.
Median B-line score per hemithorax was higher in the 
RT-targeted (9; 1st-3rd quartiles: 2-23) than in the con-
tralateral control (3; 1st-3rd quartiles: 1-4) hemithorax 
(Wilcoxon Signed rank test: P < 0.05).
The patients suffering from acute broncopathy 
(cough and cold) at the time of the first echo pulmo-
nary were 9 over 30 (30%) and their median of B-lines 
was 4 (1st-3rd quartiles: 3-10) in the treated side and 2 
(1st-3rd quartiles: 1-4) in the untreated side.
We considered mean lung dose (MLD) and identi-
fied two groups, MLD > 2.7 Gy and MLD < 2.7 Gy 
observing that median number of B-line in the treated 
side was higher for higher median doses, 13 and 5 re-
spectively for the two groups.
The median number of B-lines in the treated side was 
higher for patients with V95%, V90%, V50%, V20% and 
V5% over the median number.
Although not statistically significant, we found a 
trend to higher number of B-lines in older patients with 
a BMI over 25. 
We found no significant correlation with age and 
some dosimetric variables (Table 2).
DISCUSSION
Radiation lung injury is a well- known event after 
breast RT and its natural history can be divided into 5 
phases: immediate phase (hours to days); latent phase; 
acute exudative (4-12 weeks post-RT); intermediate 
phase with resolution of exudate and deposition of 
fibroblasts and the final phase when fibrosis is estab-
lished (usually 6-12 months post-RT) [16, 17]. 
Pulmonary fibrosis involves parenchyma and pleura 
and its severity seems to be related to a number of fac-
tors, including the volume of irradiated lung, radiation 
dose, fractionation and concomitant use of some che-
motherapy regimens. Additional risk factors that may 
increase the degree of damage include age, cigarette 
smoking, and pre-existing lung disease. 
There are a number of studies in the literature de-
scribing pulmonary changes following adjuvant RT in 
patients that underwent conventional surgery for breast 
cancer [18-23].
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Figure 2
Number of B lines in the comparison between treated and 
untreated hemithorax for each patient. Data are expressed 
as the median value (25th-75th percentiles and outliers, in a 
box and whiskers plot). Whiskers represent the maximum and 
minimum value of the collected data, and, with reference on 
the box related to the untreated side, that the individual points 
refer to outliers. 
Table 2
Correlation between number of B-lines in treated and untreat-
ed side and some variables
Spearman correlation coefficient
Variable Treated 
side
Untreated 
side
Age 0.28 0.08
Weeks after radiation therapy 0.13 0.83
Total dose 0.12 0.72
Number of fraction 0.09 0.58
Dose per fraction -0.12 -0.72
Dose of boost -0.24 -0.61
Number of fraction of Boost -0.09 0.24
Dose per fraction Boost -0.12 -0.72
Cumulatice dose ( Boost+WB) 0.04 0.64
PTV 0.06 -0.33
LV 0.19 -0.05
V95%(%) -0.01 0.23
V90%(%) -0.22 0.09
V50%(%) 0.17 -0.26
V20Gy(%) 0.15 -0.35
V5Gy(%) 0.13 -0.40
MLD (Gy) -0.21 0.14
PTV =  planning target volume, LV = lung volume, MLD = mean lung dose.
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Lind et al. reported that the addition radiotherapy to 
the axilla involved an increased incidence of radiation 
pneumonitis, compared to whole breast radiotherapy 
alone [24].
Another study by Lingos et al. showed that axillary/
supraclavicular radiotherapy was correlated with an in-
creased incidence of pulmonary side effects and an in-
creased incidence of radiation-induced lung injury was 
highlighted in patients receiving CHT concomitantly 
[25]. In contrast, Ooi et al. found no correlation be-
tween chemotherapy and pulmonary function or radio-
logical findings [26].
Fragkandrea et al. showed the correlation between 
pneumonitis diagnosed with images, age and dosimet-
ric parameters, but not between pneumonitis, smoking 
and fractionation type [27]. 
Another study by Dorr et al. showed that higher age 
and tamoxifen treatment significantly increased the in-
cidence of early pneumopathy [28]. 
In a meta-analysis study by Gokula et al. consider-
ing the incidence of early lung toxicity in 3-dimensional 
conformal irradiation of breast carcinomas, it was ob-
served that patients of age > 55 years have an increased 
risk of developing radiation pneumonitis [29].
Currently, chest high-resolution computed tomog-
raphy (HRCT) is considered the “gold-standard” for 
the diagnosis, disease activity and therapy monitoring 
of interstizial pulmonary fibrosis (IPF). Its value is re-
markable since it has been demonstrated also to be able 
to detect both early pulmonary changes and subclinical 
lung involvement. Despite of this, LUS is considered 
as a reliable alternative in the detection of pulmonary 
fibrosis. The US assessment of IPF is determined by the 
detection and quantification of B-lines, which consist of 
tails generated by the reflection of the US beam from 
thickened sub-pleural interlobar septa detectable in be-
tween the lung intercostal spaces (LIS) [30]
In a previous study we focused on RT-induced acute 
pulmonary complications after thoracic radiotherapy 
for breast cancer with the use of ultrasound as a diag-
nostic non-invasive tool, in about 4-9 weeks after the 
end of treatment and we showed that LUS is effective 
in detecting early lung damage after breast conserving 
radiotherapy [10].
In the present study, with the use of LUS, we exam-
ined lung late toxicity in breast cancer patients after RT. 
To observe a chronic effect we enrolled a new group of 
30 patients studied with the same protocol as the pre-
vious study. We confirmed that B-lines were more fre-
quent in radio-treated side but, with respect to “acute” 
study, we observed a lower median number of B-lines in 
the treated side [median: 9; (1st-3rd quartiles: 2-23) vs 
21; (1st-3rd quartiles: 11-31)], likely because of repair 
activity in the meantime, but the residual number of B-
lines could be expression of a late and permanent effect.
Considering the dosimetric parameters of the lung, 
we observed that dosimetric parameters of the lung in-
fluenced pulmonary fibrosis and were correlated with 
LUS changes. We observed a higher number of B-lines 
in older patients with a BMI over 25 and this seems 
to be correlated with anatomical changes that occur in 
overweight and obese patients, especially after a cer-
tain age. Furthermore, obese patients have often larger 
breast size which displace laterally and this may result 
in increasing the incidental dose delivered to the lung 
to cover PTV [31]. 
This is the first study that has shown that breast adju-
vant RT gives late sequelae sonographically detectable 
on treated versus untreated hemithorax.
Important limitations of the present study are the 
small number of patients, the different time of LUS from 
the end of RT (from three to eight years), and the lack of 
a subacute evaluation in the early months after RT. 
However, the persistence of observed B-lines asym-
metry on treated hemithorax versus untreated is reason-
ably due to asymmetry of local radio-induced changes 
in the lung tissue.
Then, our results could encourage the use of LUS in 
monitoring patients and detecting late pulmonary toxic-
ity after thoracic radiation treatments for breast cancer 
and for other cancers which require chest irradiation.
Nevertheless, further prospective studies are needed 
to evaluate the applications of LUS in detecting lung 
fibrosis in breast cancer survivors, examining a greater 
number of patients and monitoring sonographic lung B-
lines before and after RT, with a longer follow-up than 
the one applied in this analysis.
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